An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
2 other identifiers
observational
585
1 country
1
Brief Summary
This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2010
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 19, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 18, 2012
CompletedFirst Posted
Study publicly available on registry
June 20, 2012
CompletedResults Posted
Study results publicly available
September 19, 2012
CompletedApril 16, 2019
April 1, 2019
10 months
June 18, 2012
August 16, 2012
April 3, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of Subjects Satisfied With Latisse®
Overall subject satisfaction with Latisse® was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.
Day 1
Secondary Outcomes (2)
Number of Applications of Latisse® Per Week
Day 1
Percentage of Subjects Satisfied Wtih Their Eyelashes
Day 1
Study Arms (1)
Hypotrichosis of the Eyelashes
Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Interventions
Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Eligibility Criteria
Subjects with hypotrichosis of the eyelashes
You may qualify if:
- Hypotrichosis of the eyelashes
- Using bimatoprost ophthalmic solution 0.03% (Latisse®) for at least 12 months
You may not qualify if:
- Use of any over-the-counter medication(s) for eyelash growth
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Allerganlead
Study Sites (1)
Unknown Facility
Santa Ana, California, United States
Related Publications (1)
Yoelin SG, Fagien S, Cox SE, Davis PG, Campo A, Caulkins CA, Gallagher CJ. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatol Surg. 2014 Oct;40(10):1118-24. doi: 10.1097/01.DSS.0000452658.83001.d9.
PMID: 25229783BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Vice President Medical Affairs,
- Organization
- Allergan, Inc
Study Officials
- STUDY DIRECTOR
Medical Director
Allergan
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2012
First Posted
June 20, 2012
Study Start
November 19, 2010
Primary Completion
September 1, 2011
Study Completion
September 1, 2011
Last Updated
April 16, 2019
Results First Posted
September 19, 2012
Record last verified: 2019-04